Compare CVS Health Corp (CVS) vs Enbridge Inc (ENB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Enbridge Inc — how do they compare? CVS Health Corp trades at $86.82 (market cap $112.49B), while Enbridge Inc trades at $46.55 (market cap $102.60B). The key difference: CVS Health Corp and Enbridge Inc are close in size by market cap, and Enbridge Inc pays the higher dividend (6.1%). Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Enbridge Inc for 91 Days on average.
| CVS | ENB | |
|---|---|---|
Market Cap | $112.49B | $102.60B |
Volume | 8,467,392 | 3,673,079 |
Sector | Health | Energy |
52-Week High | $110.60 | $58.04 |
52-Week Low | $70.08 | $45.23 |
Typical Hold Time | 83 Days | 91 Days |
Enterprise Value | $174.83B | $184.87B |
Dividend Yield | 3.02% | 6.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% with strong analyst support (85% buy ratings) and a $111.20 consensus price target suggesting 26% upside. Recent quarterly earnings consistently beat expectations, with Q2 2026 EPS of $2.58 surpassing the $1.85 estimate. Revenue growth remains solid at $402.07 billion for 2025, though net margins compressed to 1.18%. Technical indicators show a bullish overall signal with support at $87 and resistance at $89.
The outlook remains positive given CVS's dominant market position and Medicare expansion plans, but investors face risks from reimbursement pressures and ongoing legal investigations. Earnings growth and successful execution of healthcare services integration represent the primary catalysts for continued stock appreciation.
Enbridge (ENB) trades at $45.89, down 1.4% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.46, beating expectations by 7%, and maintains a 6% dividend yield. Revenue grew to $65.19B in 2025 with net income of $7.49B, though 2026 projections show margin compression. Analyst consensus is mixed with 48% buy ratings and a $61.63 price target suggesting 34% upside potential.
ENB presents a value opportunity with discounted valuation metrics (P/E 25.27, P/S 1.72) and stable cash flows, but faces headwinds from rising interest rates and energy market volatility. The stock's current technical weakness contrasts with fundamental strength, creating potential for recovery if operational execution continues to outperform expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →
